Regal Wealth Group’s Iterum Therapeutics ITRM Stock Holding History

Regal Wealth Group’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13	Closed	–	–	152
2021 Q1	$0	Buy	+13	New	+$309	﹤0.01%	258

Other funds holding ITRM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

KFS

Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return

FNBT

FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Regal Wealth Group's ITRM Position: Q2 2021 in Review

Regal Wealth Group sold out of Iterum Therapeutics (ITRM) in Q2 2021, closing a stake of 13 shares.

Regal Wealth Group first reported a position in ITRM in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

Regal Wealth Group reported no remaining Iterum Therapeutics position as of Q2 2021 after selling out during the quarter.
Regal Wealth Group sold 13 Iterum Therapeutics shares in Q2 2021.
Regal Wealth Group first reported a position in Iterum Therapeutics in Q1 2021 and held it in 1 quarter.
Regal Wealth Group's Iterum Therapeutics position peaked at $0 in Q1 2021.
44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on Regal Wealth Group's 13F filing for Q2 2021, filed 2 Aug 2021.